Fig. 1 · Structure

Documents & Downloads

Betulin

Cat. No. A12210 CAS 473-98-3
Betulin is a triterpene with a pentacyclic ring structure and hydroxyl groups in positions C3 and C28. Betulin has protective effects against cadmium induced apoptosis in human hepatoma cell lines.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
518A2 EC50 > 30 μM Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay [PMID: 27142753]
518A2 EC50 > 30 μM Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay [PMID: 26547057]
518A2 EC50 28.8 μM Cytotoxicity against human 518A2 cells by SRB assay [PMID: 26007303]
8505C EC50 > 30 μM Cytotoxicity against human 8505C cells by SRB assay [PMID: 26007303]
A2780 IC50 > 10 μM Cytotoxicity against human A2780 cells after 96 hrs by MTT assay [PMID: 24467317]
A2780 EC50 > 30 μM Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay [PMID: 31718946]
A2780 EC50 > 30 μM Cytotoxicity against human A2780 cells after 96 hrs by SRB assay [PMID: 27142753]
A2780 EC50 > 30 μM Cytotoxicity against human A2780 cells after 96 hrs by SRB assay [PMID: 26547057]
A2780 EC50 29.3 μM Cytotoxicity against human A2780 cells by SRB assay [PMID: 26007303]
A2780 IC50 6.1 μM Cytotoxicity against human A2780 cells after 4 days by MTT assay [PMID: 19702283]
A-375 EC50 > 30 μM Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay [PMID: 31718946]
A-375 IC50 28 μM Cytotoxicity against human A375 cells after 72 hrs by MTT assay [PMID: 26280921]
A549 IC50 > 10 μM Cytotoxicity against human A549 cells after 96 hrs by MTT assay [PMID: 24467317]
A549 IC50 > 200 μM Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence [PMID: 19200744]
A549 EC50 > 30 μM Cytotoxicity against human A549 cells after 96 hrs by SRB assay [PMID: 27142753]
A549 EC50 > 30 μM Cytotoxicity against human A549 cells after 96 hrs by SRB assay [PMID: 26547057]
A549 IC50 > 316 μM Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay [PMID: 15730243]
A549 IC50 > 316 μM Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge [PMID: 15730243]
A549 IC50 18.15 μM Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay [PMID: 28671831]
A549 EC50 20.6 μM Cytotoxicity against human A549 cells by SRB assay [PMID: 26007303]
A549 IC50 3.8 μM Cytotoxicity against human A549 cells after 48 hrs [PMID: 19115839]

21 records · Scroll to view more

Betulin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Betulin from 4 published references. In vitro models include human pancreatic cell line EPP85-181P; MHCC97-H cells. In vivo models include C57BL/6 mice.

Betulin In Vitro Studies

In human pancreatic EPP85-181P (181P) cells treated with Betulin in dilution series, the sulphorhodamine B staining proliferation assay reported a value of 21.09 μM. In MHCC97-H cells carrying a reporter with a SREBP-1-binding element, Betulin decreased luciferase activity in a dose-dependent manner compared with the vehicle control. In RAW 264.7 cells, Betulin at 9, 18 and 36 μM for 6 h increased Nrf2 translocation from the cytoplasm to the nucleus. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Betulin in a pancreatic cell proliferation assay

Cell-based study · human pancreatic cell line EPP85-181P (181P) [1]

Human pancreatic cell line EPP85-181P (181P) was treated with Betulin in dilution series. The sulphorhodamine B staining-based proliferation assay reported a value of 21.09 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
proliferation assay based on sulphorhodamine B (SRB) stainingIC50 21.09 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
After attachment for 24 h, substances were added in dilution series for a 5-day incubation
Method
substances were added in dilution series
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose, control.
Methods and source locations

Compound reported in the paper: Betulin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

3. Experimental > 3.4. Purification of the betulin from the extract (S17); 3. Experimental > 3.8. Cell lines (S27); 3. Experimental > 3.10. Cell proliferation assay (S29, S31, S33); Table 1 (T1.h1, T1.r1)

proliferation assay based on sulphorhodamine B (SRB) staining: proliferation assay based on sulphorhodamine B (SRB) staining — 3. Experimental > 3.10. Cell proliferation assay (S29); Table 1 (T1.h1, T1.r1)

Betulin decreases reporter activity in MHCC97-H cells

Cell-based study · MHCC97-H cells [2]

MHCC97-H cells carrying a luciferase reporter vector with a SREBP-1-binding element were treated with Betulin. Luciferase activity decreased in a dose-dependent manner compared with the vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
luciferase activityReported result MHCC97-H cells with the reporter vectors: a luciferase reporter gene vector which harbored a SREBP-1-binding element; Betulin treatment decreased the luciferase activity in a dose-dependent manner, compared with the vehicle control.[2]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Betulin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > SREBP-1 promotes HCC cell proliferation and metastasis (S63, S64)

luciferase activity: luciferase activity; comparator: vehicle control — Results > SREBP-1 promotes HCC cell proliferation and metastasis (S63, S64)

Betulin increases nuclear translocation of Nrf2

Cell-based study · RAW 264.7 cells [3]

RAW 264.7 cells were treated with Betulin at 9, 18 and 36 μM for 6 h. Treatment increased Nrf2 translocation from the cytoplasm to the nucleus.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nuclear and cytoplasmic extracts from RAW 264.7 cells were prepared for detecting Nrf2Reported result Betulin (9, 18 and 36 μM) for 6 h: treatment with betulin increased Nrf2 translocation from cytoplasm to nucleus.[3]

Literature-Reported Treatment Conditions

Treatment concentration
9, 18 and 36 μM
Exposure duration
for 6 h
Method
treated with betulin
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Betulin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effects of betulin on Nrf2 translocation, Keap1 and antioxidant enzyme expression (S2); Figure 1 legend (S80, S81, S85)

Nuclear and cytoplasmic extracts from RAW 264.7 cells were prepared for detecting Nrf2: Nuclear and cytoplasmic extracts from RAW 264.7 cells were prepared for detecting Nrf2; comparator: the control group — Results > Effects of betulin on Nrf2 translocation, Keap1 and antioxidant enzyme expression (S2); Figure 1 legend (S80, S81)

Betulin In Vivo Studies

C57BL/6 mice received Betulin at 30 mg/kg by oral gavage every day for 2 weeks. RNA sequencing of Ang II-induced heart tissues identified 119 genes downregulated and 683 genes upregulated in the Ang II + betulin group versus the Ang II group. [4]

Betulin and gene expression in mouse heart tissues

Animal study · C57BL/6 mice [4]

C57BL/6 mice received Betulin at 30 mg/kg by oral gavage every day for 2 weeks. RNA sequencing of Ang II-induced heart tissues identified 119 genes downregulated and 683 genes upregulated in the Ang II + betulin group versus the Ang II group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RNA sequencing analysisdifferentially expressed genes 30 mg/kg; the Ang II + betulin group versus the Ang II group: 119 genes downregulated and 683 genes upregulated[4]

Conditions shared by the study groups

Route
oral gavage
Treatment course
every day for 2 weeks
Vehicle
0.5% CMC‐Na solution
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Betulin 30 mg/kgthe Ang II groupBetulin (30 mg/kg): 119 genes were downregulated and 683 genes were upregulated following betulin treatment in Ang II‐induced heart tissues; the Ang II + betulin group versus the Ang II group.[4]
Betulin 30 mg/kg
Model: C57BL/6 mice
Methods and source locations

Compound reported in the paper: Betulin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Establishment of Animal Models (S12, S26); Results > Betulin Alleviated Ang II‐Induced Cardiac Dysfunction, Hypertrophy, and Fibrosis In Vivo (S88); Results > Betulin Exerted Cardioprotective Effects via AMPK and Nrf2 Pathway Activation (S111); FIGURE 4 legend (S193, S194)

RNA sequencing analysis: RNA sequencing analysis; comparator: the Ang II group — Results > Betulin Exerted Cardioprotective Effects via AMPK and Nrf2 Pathway Activation (S111); FIGURE 4 legend (S193, S194)

Betulin 30 mg/kg · Materials and Methods > Establishment of Animal Models (S26); Results > Betulin Exerted Cardioprotective Effects via AMPK and Nrf2 Pathway Activation (S111); FIGURE 4 legend (S193, S194)

Specifications

Manufacturer Adooq Bioscience
CAS Number 473-98-3
Formula C30H50O2
Molecular Weight 442.72
SMILES
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)CO

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 22 mg/mL (49.69 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Betulin Research References

  1. [1] Drag M, Surowiak P, Drag-Zalesinska M, et al. Comparision of the cytotoxic effects of birch bark extract, betulin and betulinic acid towards human gastric carcinoma and pancreatic carcinoma drug-sensitive and drug-resistant cell lines. Molecules (2009). PMID: 19396022 DOI: 10.3390/molecules14041639 Source material
  2. [2] Yin F, Feng F, Wang L, et al. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis (2019). PMID: 31511501 DOI: 10.1038/s41419-019-1884-7 Source material
  3. [3] Ci X, Zhou J, Lv H, et al. Betulin exhibits anti-inflammatory activity in LPS-stimulated macrophages and endotoxin-shocked mice through an AMPK/AKT/Nrf2-dependent mechanism. Cell Death Dis (2017). PMID: 28518138 DOI: 10.1038/cddis.2017.39 Source material
  4. [4] Zheng B, He M, Wu H, et al. Betulin Protects Against Cardiac Hypertrophy by Improving AMPK/Nrf2-Dependent Mitochondrial Function. Phytother Res (2026). PMID: 41804091 DOI: 10.1002/ptr.70296 Source material

Added to your cart

View Cart Checkout
Loading...